Volasertib (BI 6727) trihydrochloride 是一种具有口服活性的、高效的、ATP 竞争性的 Polo 样激酶 1 (PLK1) 抑制剂，IC50为 0.87 nM。Volasertib trihydrochloride 抑制 PLK2 和 PLK3，IC50分别为 5 和 56 nM。Volasertib trihydrochloride 诱导有丝分裂停滞和细胞凋亡。Volasertib trihydrochloride 是一种二氢蝶呤酮衍生物，在多种癌症模型中显示出显着的抗肿瘤活性。
| 生物活性 | Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitivePolo-like kinase1 (PLK1)inhibitor with anIC50of 0.87 nM. Volasertib trihydrochloride inhibitsPLK2andPLK3withIC50s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest andapoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiplecancermodels[1][2]. |
| IC50& Target[1] | PLK1 0.87 nM (IC50) | PLK2 5 nM (IC50) | PLK3 56 nM (IC50) |
|
体外研究
(In Vitro) | Volasertib trihydrochloride (BI 6727 trihydrochloride; 0.01-10000 nM; 72 hours) has EC50values of 11 to 37 nmol/L in multiple cell lines[1].
Volasertib trihydrochloride (10-1000 nM; 24 hours) results accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase[1].
Volasertib trihydrochloride (100 nM; 24-72 hours) induces cell apoptosis at 48 hours[1].
Cell Proliferation Assay[1] | Cell Line: | Multiple cell lines | | Concentration: | 0.01-10000 nM | | Incubation Time: | 72 hours | | Result: | Inhibited proliferation of multiple cell lines derived from various cancer tissues, including carcinomas of the colon (HCT 116, EC50=23 nmol/L) and lung (NCI-H460, EC50=21 nmol/L), melanoma (BRO, EC50=11 nmol/L), and hematopoietic cancers (GRANTA-519, EC50=15 nmol/L; HL-60, EC50=32 nmol/L; THP-1, E50=36 nmol/L and Raji, EC50=37 nmol/L) with EC50values of 11 to 37 nmol/L. |
Apoptosis Analysis[1] | Cell Line: | NCI-H460 cells | | Concentration: | 100 nM | | Incubation Time: | 24, 48, 72 hours | | Result: | G2-M arrest at 24 hours was followed by induction of apoptosis at 48 hours. |
Cell Cycle Analysis[1] | Cell Line: | NCI-H460 cells | | Concentration: | 10, 30, 100, 300, 1000 nM | | Incubation Time: | 24 hours | | Result: | Resulted in accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase. |
|
体内研究
(In Vivo) | Volasertib trihydrochloride (BI 6727 trihydrochloride; A total weekly dose of 50 mg/kg; Oral; once a week, twice a week, or daily; for 40 days) shows comparable efficacy in human colon carcinoma xenograft models[1].
Volasertib trihydrochloride (15, 20, or 25 mg/kg/day; i.v.; 2 consecutive days per week; for 40 days) leads to significant tumor growth delay and even tumor regression in human colon carcinoma xenograft models[1].
Volasertib trihydrochloride (70 mg/kg given once weekly or 10 mg/kg daily; oral) significantly delays tumor growth in a non-small cell lung carcinoma xenograft model derived from NCI-H460 cells[1].
Volasertib (a single dose of 40 mg/kg; iv) causes a significant (13-fold) increase in mitotic cells in HCT 116 tumor-bearing nude mice[1].
Volasertib has high volume of distribution and a long terminal half-life in mice (Vss=7.6 L/kg, t1/2=46 h) and rats (Vss=22 L/kg, t1/2=54 h)[1].
| Animal Model: | Female BomTac:NMRI-Foxn1numice (Taconic) were grafted s.c. with HCT 116 human colon carcinoma cells (ATCC CCL-247)[1] | | Dosage: | A total weekly dose of 50 mg/kg | | Administration: | Oral; once a week, twice a week, or daily; for 40 days | | Result: | Showed comparable efficacy and were well tolerated. |
| Animal Model: | Female BomTac:NMRI-Foxn1numice and male Wistar rats of the strain Crl:WI[1] | | Dosage: | 35 mg/kg (mice) or 10 mg/kg (rat) (Pharmacokinetic Analysis) | | Administration: | IV 5-minute infusion; a single dose 5-minute infusion | | Result: | Had high volume of distribution and a long terminal half-life in mice (Vss=7.6 L/kg, t1/2=46 h) and rats (Vss=22 L/kg, t1/2=54 h). |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com